A detailed history of Assenagon Asset Management S.A. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 186,039 shares of SAGE stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
186,039
Previous 167,225 11.25%
Holding current value
$1.07 Million
Previous $1.82 Million 26.16%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$7.02 - $13.08 $132,074 - $246,087
18,814 Added 11.25%
186,039 $1.34 Million
Q2 2024

Jul 18, 2024

BUY
$10.58 - $17.9 $112,486 - $190,312
10,632 Added 6.79%
167,225 $1.82 Million
Q1 2024

Apr 24, 2024

BUY
$18.62 - $26.95 $2.66 Million - $3.86 Million
143,075 Added 1058.4%
156,593 $2.93 Million
Q4 2023

Jan 17, 2024

BUY
$17.1 - $22.26 $231,157 - $300,910
13,518 New
13,518 $292,000
Q2 2023

Jul 25, 2023

SELL
$40.65 - $59.54 $2.89 Million - $4.23 Million
-71,126 Reduced 68.57%
32,605 $1.53 Million
Q1 2023

Apr 18, 2023

BUY
$37.27 - $46.57 $257,051 - $321,193
6,897 Added 7.12%
103,731 $4.35 Million
Q3 2022

Oct 27, 2022

SELL
$32.28 - $43.27 $2.51 Million - $3.36 Million
-77,617 Reduced 44.49%
96,834 $3.79 Million
Q2 2022

Jul 27, 2022

BUY
$27.52 - $37.99 $4.8 Million - $6.63 Million
174,451 New
174,451 $5.64 Million
Q4 2021

Feb 01, 2022

SELL
$37.06 - $47.11 $1.19 Million - $1.51 Million
-32,017 Closed
0 $0
Q3 2021

Oct 19, 2021

BUY
$40.26 - $57.37 $334,158 - $476,171
8,300 Added 35.0%
32,017 $1.42 Million
Q2 2021

Jul 15, 2021

BUY
$54.88 - $79.29 $425,704 - $615,052
7,757 Added 48.6%
23,717 $1.35 Million
Q1 2021

Apr 26, 2021

BUY
$70.65 - $96.76 $1.13 Million - $1.54 Million
15,960 New
15,960 $1.2 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.